Do analysts prefer ALBT or NMTR?

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than Avalon GloboCare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ALBT or NMTR more profitable?

Avalon GloboCare's return on equity of 0.00% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% 9 Meters Biopharma N/A -584.97% -159.45%

Do analysts recommend CELZ or NMTR?

Given 9 Meters Biopharma's higher probable upside, analysts plainly believe 9 Meters Biopharma is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CELZ or NMTR more profitable?

Creative Medical Technology's return on equity of -88.38% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% 9 Meters Biopharma N/A -584.97% -159.45%

Do analysts recommend CAPS or NMTR?

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than Capstone Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend NMTR or BDRX?

Given 9 Meters Biopharma's higher probable upside, equities analysts clearly believe 9 Meters Biopharma is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, NMTR or BDRX?

Biodexa Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A Biodexa Pharmaceuticals $470K 7.02 -$8.42M N/A N/A

Is NMTR or BDRX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets 9 Meters Biopharma N/A -584.97% -159.45% Biodexa Pharmaceuticals N/A N/A N/A

9 Meters Biopharma (NMTR) Competitors

Compare

NMTR vs. SXTP, ALBT, CELZ, CAPS, and BDRX

Should you buy 9 Meters Biopharma stock or one of its competitors? MarketBeat compares 9 Meters Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 9 Meters Biopharma include 60 Degrees Pharmaceuticals (SXTP), Avalon GloboCare (ALBT), Creative Medical Technology (CELZ), Capstone Therapeutics (CAPS), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry.

How does 9 Meters Biopharma compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than 9 Meters Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for 9 Meters Biopharma. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat 9 Meters Biopharma's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Very Positive
9 Meters Biopharma	Neutral

9 Meters Biopharma has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
9 Meters Biopharma	N/A	-584.97%	-159.45%

60 Degrees Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Summary

60 Degrees Pharmaceuticals beats 9 Meters Biopharma on 10 of the 15 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Avalon GloboCare?

Avalon GloboCare (NASDAQ:ALBT) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Avalon GloboCare's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Avalon GloboCare has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Avalon GloboCare has higher revenue and earnings than 9 Meters Biopharma. Avalon GloboCare is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	3.22	-$18.26M	-$3.51	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

In the previous week, Avalon GloboCare had 4 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 4 mentions for Avalon GloboCare and 0 mentions for 9 Meters Biopharma. Avalon GloboCare's average media sentiment score of 0.72 beat 9 Meters Biopharma's score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Overall Sentiment
Avalon GloboCare	Positive
9 Meters Biopharma	Neutral

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Avalon GloboCare beats 9 Meters Biopharma on 8 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Creative Medical Technology?

Creative Medical Technology (NASDAQ:CELZ) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Creative Medical Technology has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Creative Medical Technology's return on equity of -88.38% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
9 Meters Biopharma	N/A	-584.97%	-159.45%

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Creative Medical Technology has higher revenue and earnings than 9 Meters Biopharma. Creative Medical Technology is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	383.94	-$5.99M	-$2.14	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Given 9 Meters Biopharma's higher probable upside, analysts plainly believe 9 Meters Biopharma is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Creative Medical Technology had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Creative Medical Technology and 0 mentions for 9 Meters Biopharma. Creative Medical Technology's average media sentiment score of 1.45 beat 9 Meters Biopharma's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Positive
9 Meters Biopharma	Neutral

Summary

Creative Medical Technology beats 9 Meters Biopharma on 9 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Capstone Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than Capstone Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Capstone Therapeutics has a beta of -1.51, suggesting that its share price is 251% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, Capstone Therapeutics had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Capstone Therapeutics and 0 mentions for 9 Meters Biopharma. Capstone Therapeutics' average media sentiment score of 1.87 beat 9 Meters Biopharma's score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Capstone Therapeutics	Very Positive
9 Meters Biopharma	Neutral

9 Meters Biopharma has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Capstone Therapeutics has higher revenue and earnings than 9 Meters Biopharma. Capstone Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.07	-$21.23M	-$3.37	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Summary

Capstone Therapeutics beats 9 Meters Biopharma on 9 of the 14 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Biodexa Pharmaceuticals?

9 Meters Biopharma (NASDAQ:NMTR) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 0 mentions for 9 Meters Biopharma. Biodexa Pharmaceuticals' average media sentiment score of 1.43 beat 9 Meters Biopharma's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
9 Meters Biopharma	Neutral
Biodexa Pharmaceuticals	Positive

9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Given 9 Meters Biopharma's higher probable upside, equities analysts clearly believe 9 Meters Biopharma is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
9 Meters Biopharma	N/A	-584.97%	-159.45%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Biodexa Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A
Biodexa Pharmaceuticals	$470K	7.02	-$8.42M	N/A	N/A

22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Biodexa Pharmaceuticals beats 9 Meters Biopharma on 7 of the 11 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMTR vs. The Competition

Export

Metric	9 Meters Biopharma	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04M	$443.68M	$7.06B	$12.20B
Dividend Yield	N/A	3.90%	2.67%	9.41%
P/E Ratio	0.00	3.49	27.14	23.63
Price / Sales	N/A	6,592.41	582.30	111.98
Price / Cash	N/A	13.13	49.81	58.78
Price / Book	N/A	83.70	10.28	6.01
Net Income	-$43.77M	-$96.07M	$3.60B	$331.99M

9 Meters Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$1.04M	N/A	N/A	20
SXTP 60 Degrees Pharmaceuticals	3.2296 of 5 stars	$1.49 -3.9%	$13.85 +829.5%	-71.8%	$4.12M	$1.41M	N/A	3
ALBT Avalon GloboCare	0.3127 of 5 stars	$0.28 -1.1%	N/A	-87.7%	$4.05M	$1.26M	N/A	5	Short Interest Increase High Trading Volume
CELZ Creative Medical Technology	1.5116 of 5 stars	$0.81 -3.6%	N/A	-70.1%	$3.99M	$10K	N/A	5	Short Interest Decrease
CAPS Capstone Therapeutics	0.7316 of 5 stars	$0.24 +2.8%	N/A	-85.6%	$3.62M	$48.11M	N/A	38

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMTR) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

9 Meters Biopharma (NMTR) Competitors

NMTR vs. SXTP, ALBT, CELZ, CAPS, and BDRX

How does 9 Meters Biopharma compare to 60 Degrees Pharmaceuticals?

Summary

How does 9 Meters Biopharma compare to Avalon GloboCare?

Summary

How does 9 Meters Biopharma compare to Creative Medical Technology?

Summary

How does 9 Meters Biopharma compare to Capstone Therapeutics?

Summary

How does 9 Meters Biopharma compare to Biodexa Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR vs. The Competition

9 Meters Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

9 Meters Biopharma (NMTR) Competitors

NMTR vs. SXTP, ALBT, CELZ, CAPS, and BDRX

How does 9 Meters Biopharma compare to 60 Degrees Pharmaceuticals?

Do analysts recommend SXTP or NMTR?

Which has more risk and volatility, SXTP or NMTR?

Do insiders and institutionals believe in SXTP or NMTR?

Does the media prefer SXTP or NMTR?

Is SXTP or NMTR more profitable?

Which has higher valuation & earnings, SXTP or NMTR?

Summary

How does 9 Meters Biopharma compare to Avalon GloboCare?

Is ALBT or NMTR more profitable?

Which has more risk and volatility, ALBT or NMTR?

Do analysts prefer ALBT or NMTR?

Which has preferable earnings & valuation, ALBT or NMTR?

Does the media refer more to ALBT or NMTR?

Do insiders & institutionals hold more shares of ALBT or NMTR?

Summary

How does 9 Meters Biopharma compare to Creative Medical Technology?

Which has more volatility & risk, CELZ or NMTR?

Is CELZ or NMTR more profitable?

Do institutionals and insiders believe in CELZ or NMTR?

Which has better valuation and earnings, CELZ or NMTR?

Do analysts recommend CELZ or NMTR?

Does the media prefer CELZ or NMTR?

Summary

How does 9 Meters Biopharma compare to Capstone Therapeutics?

Do analysts recommend CAPS or NMTR?

Do institutionals & insiders believe in CAPS or NMTR?

Which has more risk and volatility, CAPS or NMTR?

Does the media prefer CAPS or NMTR?

Is CAPS or NMTR more profitable?

Which has higher earnings & valuation, CAPS or NMTR?

Summary

How does 9 Meters Biopharma compare to Biodexa Pharmaceuticals?

Does the media favor NMTR or BDRX?

Which has more risk & volatility, NMTR or BDRX?

Do analysts recommend NMTR or BDRX?

Is NMTR or BDRX more profitable?

Which has preferable earnings and valuation, NMTR or BDRX?

Do insiders & institutionals believe in NMTR or BDRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR vs. The Competition

9 Meters Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools